Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Biogen

TECFIDERA drives revenues in 2015

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen

4Q Revenues: $2.8 billion (+8%)

4Q Earnings: $828.7 million (-6%)

FY Revenues: $10.8 billion (+11%)

FY Earnings: $3.5 billion (+21%)

Comments: TECFIDERA revenues were $3.6 billion for the year, up 24%, with $2.9 billion in U.S. sales and $730 million in sales outside the U.S. Interferon revenues, including AVONEX and PLEGRIDY, were $3.0 billion, down 3%, with $2.0 billion in U.S. sales and $951 million in sales outside the U.S. TYSABRIrevenues were $1.9 billion, down 5%, with $1.1 billion in U.S. sales and $783 million in sales outside the U.S. Revenues relating to RITUXAN and GAZYVA from Biogen’s unconsolidated joint business arrangement were $1.3 billion, up 8%. Royalty revenues were $48 million compared to $177 million in 2014.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters